We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Discovery of MK-1088 highlights its potential as a dual-antagonist targeting A2A and A2B adenosine receptors for enhancing cancer immunotherapy.
) being identified for progression to human clinical studies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: